Teachers Retirement System of The State of Kentucky boosted its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) by 319.7% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 16,814 shares of the medical research company’s stock after purchasing an additional 12,808 shares during the period. Teachers Retirement System of The State of Kentucky’s holdings in Charles River Laboratories International were worth $4,960,000 at the end of the most recent quarter.
Other institutional investors and hedge funds also recently bought and sold shares of the company. Dimensional Fund Advisors LP raised its position in shares of Charles River Laboratories International by 14.6% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,652,484 shares of the medical research company’s stock valued at $285,001,000 after purchasing an additional 210,260 shares during the period. Aberdeen Group plc lifted its stake in shares of Charles River Laboratories International by 483.6% during the 3rd quarter. Aberdeen Group plc now owns 792,576 shares of the medical research company’s stock valued at $233,818,000 after buying an additional 656,777 shares in the last quarter. Bank of America Corp DE lifted its stake in shares of Charles River Laboratories International by 5.0% during the 1st quarter. Bank of America Corp DE now owns 1,135,027 shares of the medical research company’s stock valued at $195,792,000 after buying an additional 54,500 shares in the last quarter. Amundi boosted its holdings in Charles River Laboratories International by 175.2% in the 1st quarter. Amundi now owns 773,315 shares of the medical research company’s stock worth $133,397,000 after buying an additional 492,301 shares during the period. Finally, Russell Investments Group Ltd. boosted its holdings in Charles River Laboratories International by 457.3% in the 3rd quarter. Russell Investments Group Ltd. now owns 436,055 shares of the medical research company’s stock worth $128,641,000 after buying an additional 357,817 shares during the period. 98.91% of the stock is currently owned by hedge funds and other institutional investors.
Insider Activity at Charles River Laboratories International
In other news, EVP Shannon M. Parisotto sold 2,156 shares of the company’s stock in a transaction on Wednesday, October 21st. The stock was sold at an average price of $344.41, for a total transaction of $742,547.96. Following the transaction, the executive vice president directly owned 4,807 shares of the company’s stock, valued at approximately $1,655,578.87. This represents a 30.96% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director James Foster sold 24,042 shares of the stock in a transaction on Thursday, October 22nd. The shares were sold at an average price of $350.00, for a total value of $8,414,700.00. Following the sale, the director owned 31,596 shares of the company’s stock, valued at approximately $11,058,600. This represents a 43.21% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 60,740 shares of company stock valued at $19,528,128. 1.30% of the stock is owned by insiders.
Analyst Upgrades and Downgrades
Several brokerages recently issued reports on CRL. Wall Street Zen raised Charles River Laboratories International from a “hold” rating to a “buy” rating in a research note on Saturday, November 7th. Royal Bank Of Canada boosted their price target on Charles River Laboratories International from $322.00 to $352.00 and gave the stock an “outperform” rating in a report on Thursday, November 5th. Evercore set a $330.00 price target on Charles River Laboratories International in a research note on Friday, September 25th. JPMorgan Chase & Co. raised shares of Charles River Laboratories International from a “neutral” rating to an “overweight” rating and increased their price objective for the company from $180.00 to $310.00 in a report on Thursday, August 6th. Finally, Barclays lifted their price objective on shares of Charles River Laboratories International from $330.00 to $375.00 and gave the company an “overweight” rating in a research report on Thursday, November 5th. Twelve analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $311.67.
View Our Latest Stock Report on Charles River Laboratories International
Charles River Laboratories International Price Performance
Shares of CRL stock opened at $333.47 on Thursday. The stock’s 50-day moving average is $314.26 and its 200 day moving average is $230.05. Charles River Laboratories International, Inc. has a 1-year low of $146.20 and a 1-year high of $379.63. The company has a debt-to-equity ratio of 0.76, a current ratio of 1.41 and a quick ratio of 1.12. The company has a market cap of $15.98 billion, a P/E ratio of 366.45, a PEG ratio of 3.00 and a beta of 1.36.
Charles River Laboratories International (NYSE:CRL – Get Free Report) last announced its earnings results on Wednesday, November 4th. The medical research company reported $3.09 EPS for the quarter, topping analysts’ consensus estimates of $2.97 by $0.12. Charles River Laboratories International had a net margin of 1.01% and a return on equity of 16.95%. The business had revenue of $982.73 million during the quarter, compared to the consensus estimate of $960.36 million. During the same period in the previous year, the company posted $2.43 earnings per share. The firm’s revenue was down 2.2% on a year-over-year basis. Research analysts predict that Charles River Laboratories International, Inc. will post 11.45 earnings per share for the current fiscal year.
Charles River Laboratories International Profile
Charles River Laboratories International is a contract research organization that supports pharmaceutical and biotechnology companies, as well as academic and government researchers, in developing medicines and advancing scientific research. Its services span the drug development process, from early discovery and preclinical research to manufacturing support. The company’s offerings include research models and related services, drug discovery and safety assessment, and manufacturing solutions. These may include laboratory animal models, laboratory testing, bioanalysis, and support for the production of products used in the development of pharmaceuticals and biologics.
See Also
- Five stocks we like better than Charles River Laboratories International
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.
